###### Key points

-   CHD mortality fell by 20% between 1998 and 2009 in the West Bank.

-   More than two-third of this fall was due to decreases in major risk factors, particularly total cholesterol, and blood pressure.

Introduction {#s1}
============

The occupied Palestinian territory (oPt) comprises the Gaza Strip and the West Bank including East Jerusalem. Some 46% of the Palestinian population of 3.8 million are younger than 15 years while only 3% are older than 65 years. However, the number of older people is increasing gradually and the population is slowly ageing. The Palestinians are also undergoing rapid epidemiological transition. Communicable diseases of childhood have already been controlled with effective immunisation programmes, and poliomyelitis has been eradicated. However, non-communicable diseases have now overtaken communicable diseases as the main causes of mortality.[@R1] Thus, cardiovascular disease (CVD) and cancer are now the major causes of morbidity and mortality in the oPt.[@R2] The Ministry of Heath (MOH) recently reported that 25% of all deaths are due to cardiovascular diseases in 2010, followed by cerebrovascular diseases (12%), cancer (11%) and diabetes (6%).[@R3] Increasing levels of adverse risk factors such as diabetes, obesity and physical inactivity have been repeatedly documented.[@R4] [@R5]

Chronic disease death rates are actually decreasing in the developed world (Western Europe, North America, Australia and New Zealand). However, mortality is increasing in the developing countries. It is predicted that by 2020, CVD deaths will exceed infectious and parasitic disease deaths in all regions except for sub-Saharan Africa.[@R6] Furthermore, the Eastern Mediterranean region has been recognised as a hot spot for diabetes and CVD, yet local data to inform policy is severely limited.

The IMPACT coronary heart disease (CHD) model was developed to quantify recent trends in CHD mortality, in order to help maximise the effective use of existing information and resources to develop appropriate policies and strategies. This study aims to adopt the IMPACT CHD model to the Palestinian context, namely the West Bank population, in order to help explain recent changes in CHD mortality.

Methods {#s2}
=======

A validated version of the IMPACT CHD mortality model was further modified and updated to suit the countries in the Middle East and specifically the oPt. The IMPACT model was previously validated in many developed countries[@R7; @R8; @R9; @R10] and in one middle-income country (China).[@R11]

Palestinian data on risk factors levels and current uptake levels of evidence-based treatments were identified by extensive searches for published or unpublished data and complemented with specifically designed surveys. All data sources were critically appraised by the local research team and the results are presented in the [appendix](http://.oxfordjournals.org/lookup/suppl/doi:10.1093//bmjopen-2012-001061/-/DC1). The data needed for the analysis were available for men and women aged 25--75 years in the West Bank, occupied Palestinian territory for the period 1998--2009 with some age limitations as described in the [appendix](http://.oxfordjournals.org/lookup/suppl/doi:10.1093//bmjopen-2012-001061/-/DC1).

The specific data items used to populate the model included: (1) Patient numbers in specific CHD groups (myocardial infarction (MI), congestive heart failure and chronic angina pectoris), (2) uptake of specific medical and surgical treatments, (3) population trends in major cardiovascular risk factors (smoking, total cholesterol, systolic blood pressure, body mass index (BMI), diabetes and physical inactivity).

The main output of the model is the number of deaths prevented or postponed attributed to the changes in specific treatments and/or risk factor levels.

Identification and assessment of relevant data {#s2a}
----------------------------------------------

Information on the West Bank *population demographic changes* was obtained and validated for the first year from 1997 census-based projections and 2007 census-based projections for the final year by the Palestinian Central Bureau of Statistics (PCBS).[@R12] *Numbers of deaths for both years* were obtained from the Health Information Management Centre---Palestinian Ministry of Health (MOH). *Population risk factors trend data* for the year 1998 were obtained from two epidemiological studies conducted in the rural and urban areas of Ramallah governorate in the West Bank. These were the only available published epidemiological studies in the West Bank for that period. They covered a rural and an urban site that were prototypic of many West Bank villages and urban sites.[@R4] [@R13]

*CHD numbers of hospital admissions in addition to treatment uptake* were obtained from our treatment uptake survey conducted in 2009 which included four hospitals in the north, centre and south of the West Bank. The number of patients undergoing coronary artery bypass grafting and angioplasty were obtained from records in the two hospitals providing this service in the West Bank. The prevalence of angina, heart attack survivors and congestive heart failure in the community were each estimated on the basis of national health surveys and treatment uptake surveys. Information on treatment uptake in the community was also checked by eliciting expert opinion from practising clinicians.

*The efficacy of therapeutic interventions* was based on recent meta-analyses and randomised controlled trials. The Mant and Hicks[@R14] approach was used to correct for polypharmacy.

Change in CHD deaths {#s2b}
--------------------

First, the number of CHD deaths *expected* in 2009 was calculated by indirect age standardisation based on the assumption that 1998 death rates had persisted unchanged until 2009. The number of CHD deaths actually *observed* in 2009 was then subtracted. The difference between the two represents the fall in CHD deaths (the number of deaths prevented or postponed) that the model needed to explain.

Mortality changes attributed to risk factor trends {#s2c}
--------------------------------------------------

The number of deaths prevented or postponed from changes in risk factors was estimated using two approaches. The regression β coefficients approach was used to quantify the population mortality impact of change in those specific risk factors, measured as continuous variables (blood pressure, total cholesterol and BMI). The second approach, population-attributable risk fraction, was employed for categorical variables---diabetes, physical inactivity and smoking:

PAR calculation was stratified by age and sex. Details of model methodology have been published previously[@R7] and worked examples are shown in the [appendix](http://.oxfordjournals.org/lookup/suppl/doi:10.1093//bmjopen-2012-001061/-/DC1).

Estimating the contribution of medical and surgical treatments {#s2d}
--------------------------------------------------------------

The model aimed to include all medical and surgical treatments in 1998 (the base year) and 2009 (the final year). Treatment uptake data were not available for the year 1998 and thus the data included in the model for this year was estimated after consultation with cardiologists and experts working in hospital and community at that time.

The mortality reduction for each treatment for the number of patients in each group, stratified by age and sex, was calculated as the age-specific case death in that group multiplied by the relative mortality reduction reported in published meta-analyses multiplied by the treatment uptake (the proportion of patients receiving that specific treatment, [appendix](http://.oxfordjournals.org/lookup/suppl/doi:10.1093//bmjopen-2012-001061/-/DC1)).

Case- death data were obtained from large, unselected, population-based patient cohorts. The survival benefit over a 1-year time interval was used for all treatments.

Treatment overlaps {#s2e}
------------------

Potential overlaps between different groups of patients were identified and appropriate adjustments were made. Patients group calculations and assumptions are detailed in the [appendix](http://.oxfordjournals.org/lookup/suppl/doi:10.1093//bmjopen-2012-001061/-/DC1).

Treatment adherence {#s2f}
-------------------

Adherence (defined as the proportion of treated patients actually taking therapeutically effective levels of the prescribed medication) was assumed to be 100% among hospital patients, 70% among all symptomatic community patients and 50% among asymptomatic community patients, based on the literature.[@R15]

Sensitivity analyses {#s2g}
--------------------

Because of the uncertainties surrounding some of the values, multiway sensitivity analyses using the Brigg\'s analysis of extremes method was used.[@R16]

Model validation: comparison with observed mortality falls {#s2h}
----------------------------------------------------------

The model *estimate* for the changes in deaths attributed to all treatments plus all risk factor changes was summed for men and women in each specific age group. The model fit was then compared with the *observed change* in mortality for that group.

Results {#s3}
=======

Between 1998 and 2009 CHD mortality in the West Bank fell by 20%. This resulted in approximately 125 fewer CHD deaths compared with the expected number of CHD deaths in 2009 if 1998 death rate had persisted unchanged ([table 1](#BMJOPEN2012001061TB1){ref-type="table"}).

###### 

Population sizes and coronary heart disease death rates in the West Bank, 1998 and 2009

                                    Age groups                                    
  --------------------------------- ------------ -------- ------- ------- ------- --------
  Men                                                                             
   Population in 1998               132084       80434    41727   28653   19524   302422
   Population in 2009               177873       132945   86399   41984   21619   460820
   Deaths in 1998 (number)          9            21       57      101     130     318
   Deaths in 2009 (number)          11           30       89      131     133     394
   Death rates per 100000 in 1998   6.4          26.1     135.4   350.7   665.8   105.2
   Death rates per 100000 in 2009   6.2          22.8     103.4   311.2   616.7   85.5
   Percentage of change (crude)     0            −12.6    −23.6   −11.3   −7.4    −19
  Women                                                                           
   Population in 1998               125493       76747    45711   36038   24445   308434
   Population in 2009               170942       127590   80883   43693   28424   451532
   Deaths in 1998 (number)          5            9        22      59      107     202
   Deaths in 2009 (number)          5            11       20      51      105     192
   Death rates per 100000 in 1998   3.6          11.1     48.1    162.3   437.7   65.5
   Death rates per 100000 in 2009   3.1          8.9      24.7    116.0   370.6   42.5
   Percentage of change (crude)     0            −19.8    −48.6   −28.6   −15.3   −35

The reduction in CHD mortality among women (35%) was twice as large as the 19% reduction observed among men. The CHD mortality reduction was seen in all age groups with particularly large reductions being observed among those aged 45--54 years, men (24%) and women (49%).

Major CHD risk factors {#s3a}
----------------------

Changes in cardiovascular risk factors included in the model were together estimated to prevent or postpone approximately 80 deaths in 2009 (minimum estimate 75 and maximum estimate 140), which represented approximately 66% of the total CHD mortality fall ([figure 1](#BMJOPEN2012001061F1){ref-type="fig"})*.*[Table 2](#BMJOPEN2012001061TB2){ref-type="table"} presents changes in the selected risk factors and the attributed deaths. Changes in risk factors were complex: reduction in total cholesterol (mean reduction 0.34mmol/l in men and 0.22 mmol/l in women), blood pressure (5.27 mm Hg in men and 0.01 mm Hg in women) and in smoking prevalence (11.5% in men and 2.2% in women). These changes together prevented or postponed approximately 125 deaths ([table 2](#BMJOPEN2012001061TB2){ref-type="table"}). A total fall of 40% in CHD deaths were thus attributable to cholesterol reduction (minimum 38% and maximum 77%), and 36% to blood pressure reduction (minimum 30% and maximum 50%) and 33% to smoking reduction (minimum 22% and maximum 49%). However, an additional 45 deaths were attributable to adverse trends ([figure 2](#BMJOPEN2012001061F2){ref-type="fig"}). Mainly an increase in diabetes prevalence (8.5% in men and 2% in women) generated approximately 30 additional deaths. The mortality effects of increases in physical inactivity and mean BMI were relatively modest ([table 2](#BMJOPEN2012001061TB2){ref-type="table"}).

![Coronary heart disease deaths prevented or postponed by treatment and risk factor changes in the West Bank population between 1998 and 2009.](bmjopen2012001061f01){#BMJOPEN2012001061F1}

###### 

Deaths attributable to population risk factor changes in the West Bank between 1998 and 2009

  Risk factors                                                 Risk factor levels   Absolute change in risk factor 1998--2009   Relative risk (or β coefficient)   Deaths prevented or postponed                     
  ------------------------------------------------------------ -------------------- ------------------------------------------- ---------------------------------- ------------------------------- ----- ----- ----- -------
  Cholesterol (total) (mmol/l)                                                                                                                                                                     49    46    94    −40.3
   Cholesterol (men)                                           5.37                 5.03                                        0.34                               βετα  0.65                                        
   Cholesterol (women)                                         5.25                 5.03                                        0.22                               βετα 0.65                                         
  Smoking (total) (%)                                                                                                                                                                              40    26    59    −32.5
   (% men smoking)                                             51.5                 40                                          11.5                                                                                 
   (% women smoking)                                           5.5                  3.3                                         2.2                                                                                  
  Body mass index (BMI) (total) (kg/m^2^)                                                                                       −2                                 −2                              −5    −2          
   BMI (men)                                                   26.95                30.88                                       −3.93                              βετα 0.02                                         
   BMI (women)                                                 29.12                30.99                                       −1.87                              βετα 0.02                                         
  Diabetes (total) %                                                                                                                                                                               −32   −27   −60   26.2
   Percentage of diabetes (men)                                9.1                  17.6                                        −8.5                               2                                                 
   Percentage of diabetes (women)                              12.4                 14.4                                        −2                                 2                                                 
  Population systolic blood pressure (BP) (total) mm Hg        43                   39                                          84                                 −35.6                                             
   Population BP (men)                                         125.57               120.3                                       5.27                               βετα 0.053                                        
   Population BP (women)                                       118.44               118.45                                      −0.01                              βετα a0.053                                       
  Population BP after adjustment for hypertension treatments   38                   37                                          61                                 −31.5                                             
  Physical inactivity                                                                                                                                                                              −12   −8    −17   9.7
    Percentage of physical inactivity men                      79.3                 91.3                                        12                                                                                   
    Percentage of physical inactivity women                    87.9                 93                                          5.1                                                                                  
  Estimated total risk factor effects                          81                   73                                          138                                −66.5                                             

![Coronary heart disease deaths prevented or postponed attributable to specific risk factor changes in Palestine 1998--2009: Sensitivity analysis (▪, best estimate; bars indicate minimum and maximum estimates).](bmjopen2012001061f02){#BMJOPEN2012001061F2}

![Coronary heart disease deaths prevented or postponed attributable to specific treatments in Palestine 1998--2009: Sensitivity analysis (▪, best estimate; bars indicate minimum and maximum estimates).](bmjopen2012001061f03){#BMJOPEN2012001061F3}

Medical and surgical treatments {#s3b}
-------------------------------

Medical and surgical treatments together prevented or postponed approximately 35 deaths in 2009 (minimum estimate 20 and maximum estimate 108; [figure 3](#BMJOPEN2012001061F3){ref-type="fig"}). The total treatments thus accounted for approximately 29% (minimum 17% and maximum 82%) of the total CHD mortality reduction ([table 3](#BMJOPEN2012001061TB3){ref-type="table"}). Secondary prevention following acute MI explained over 7% (minimum 3% and maximum 25%) of deaths prevented or postponed (with ACE inhibitors, aspirin and β-blockers and β-blockers being the main contributors in this group; [table 3](#BMJOPEN2012001061TB3){ref-type="table"}). Smaller contributions came from chronic angina treatment (6%, minimum 5% and maximum 11%) and heart failure treatment in the community (5%, minimum 3% and maximum 10%) and hypertensive treatment in the community (4%, minimum 1% and maximum 19%). Secondary prevention postrevascularisation had a very modest effect on CHD mortality reduction with a contribution of 2% (minimum 1% and maximum 5%; [table 3](#BMJOPEN2012001061TB3){ref-type="table"}).

###### 

Deaths prevented or postponed by medical and surgical treatments in the West Bank in 2009

                                                                           Coronary heart disease deaths prevented or postponed   Proportion of overall deaths prevented or postponed (%)         
  -------------------------------------------------------- ------- ------- ------------------------------------------------------ --------------------------------------------------------- ----- -------
  Acute myocardial infarction                              489             2                                                      1                                                         6     −1.9
   Hospital resuscitation                                          0.06    0                                                      0                                                         1     −0.3
   Thrombolysis and aspirin                                                                                                                                                                       
   Aspirin alone                                                   0.90    5                                                      2                                                         9     −3.8
   Thrombolysis alone                                              0.39    3                                                      1                                                         6     −2.4
   β-Blockers                                                      0.58    1                                                      0                                                         2     −0.6
   ACE inhibitors                                                  0.44    1                                                      0                                                         2     −1
  Secondary preventionpostinfarction                       2266            9                                                      4                                                         30    −7.4
   Aspirin                                                         0.483   4                                                      1                                                         9     −2.9
   β-Blockers                                                      0.388   4                                                      1                                                         11    −3.6
   Aspirin and β-blockers                                          0.415   4                                                      1                                                         10    −3.4
   ACE inhibitors                                                  0.472   5                                                      2                                                         13    −4.2
   Statins                                                         0.046   0                                                      0                                                         1     −0.4
   Warfarin                                                        0.100   1                                                      0                                                         3     −0.9
   Rehabilitation                                                  0.483   1                                                      0                                                         3     −0.9
  Secondary preventionpostrevascularisation                208             2                                                      0                                                         6     − 1.9
  Angina                                                                   7                                                      6                                                         13    −5.7
    Coronary Artery Bypass Grafting surgery (2004--2005)   208     1       6                                                      3                                                         10    −4.6
   Aspirin in the community                                22180   0.47    15                                                     13                                                        40    −12.7
   Statin in the community                                 22180   0.46    20                                                     11                                                        50    −16.8
   Unstable angina                                         489             1                                                      2                                                         9     −1.1
  Heart failure                                            2811                                                                                                                                   
   Hospital patients                                       468             −2                                                     −1                                                        −8    −1.5
   Community patients                                      2342            −7                                                     −4                                                        −4    −5.4
  Hypertension treatments                                                  −5                                                     −2                                                        −23   −4.1
  Total treatment effects                                                  35                                                     20                                                        108   29

Validation and model fit {#s3c}
------------------------

In summary, when including all risk factor and treatment data, the model explained approximately 95% of the total CHD mortality reduction observed in the West Bank population between 1998 and 2009. The remaining 5% was unexplained and might reflect other, unmeasured factors. The model estimates of deaths were reasonably consistent with the observed deaths for almost all age groups. Overall, the model fit was better for men than for women. However, in the age group 45--54 the model overestimated deaths in men and women ([table 4](#BMJOPEN2012001061TB4){ref-type="table"})*.* Moreover, irrespective of whether best minimum or maximum estimates were used, the relative contributions remained relatively consistent.

###### 

Model validation: estimated versus observed changes in coronary heart disease (CHD) deaths between 1998 and 2009

                                                    Age groups                           
  ------------------------------------------------- ------------ ----- ----- ----- ----- -----
  Men                                                                                    
  Estimated fall in CHD deaths                      11           35    117   147   144   454
  Observed fall in CHD deaths                       11           30    89    131   133   394
  Discrepancy                                       0            −5    −28   −16   −11   −60
  Estimated fall/ observed fall in CHD deaths (%)   100          117   131   112   108   115
  Women                                                                                  
  Estimated fall in CHD deaths                      6            14    39    71    124   254
  Observed fall in CHD deaths                       5            11    20    51    105   192
  Discrepancy                                       −1           −3    −19   −20   −19   −62
  Estimated fall/observed fall in CHD deaths (%)    120          127   195   139   118   132

Discussion {#s4}
==========

CHDs mortality decreased by 20% in the West Bank, oPt between 1998 and 2009. Almost two-thirds of this reduction was attributable to changes in major risk factors and approximately one-third was explained by medical and surgical treatments. The recent mortality trends observed in the West Bank were thus characterised by reductions in CHD mortality similar to those observed in the developed rather than developing countries. Other studies have documented similar reductions in CHD mortality in Europe, North America and New Zealand especially since the 1980s.[@R7] [@R8] [@R17] [@R18]

The biggest CHD mortality reductions attributable to changes in major risk factors came from declines in total cholesterol and smoking, and also blood pressure in men. Interestingly, the implementation efforts of an antismoking law in 2005 might have contributed to the substantial declines in smoking prevalence.[@R19] [@R20]

However, the increasing Westernisation of diet, particularly junk food and soda represent an ominous future threat. Furthermore, diabetes, obesity and physical inactivity increased substantially between 1998 and 2009.[@R21; @R22; @R23] In the year 1998, the prevalence of obesity was 49% for women and 30% for men aged 35--64 years old.[@R24] Since then, the prevalence of obesity has increased mainly among men.[@R25] [@R26] The increase in diabetes prevalence generated approximately 30 additional CHD deaths. Rising diabetes and obesity, especially among men, represents a public health priority. Effective evidence-based interventions exist and should be considered, notably junk-food taxes, labelling and reformulation issues and advertising bans.[@R27] [@R28]

The recently developed Palestinian non-communicable diseases (NCDs) strategy adopted an integrated approach encompassing promotion, prevention and control programmes. Population-based multisectoral effective evidence-based interventions were clearly indicated to control diabetes and promote physical activity such as health promotion, fiscal measures, market control and community participation. Yet a clear vision and scope of implementation are still evolving.[@R29]

Modern medical treatments accounted for approximately 30% of the CHD mortality reduction. The scale of effect is similar to that reported in studies using the same methodology in Iceland, Sweden and Finland[@R9] but lower than the 45--50% reported for North America[@R30] and Europe.[@R8] [@R10] The biggest contributions came from aspirin and community-based medications for secondary prevention, chronic angina and heart failure. Treatment uptakes were generally mediocre and need to be improved. However, such treatments create challenges for health providers in terms of identifying patients, providing medications and ensuring their long-term compliance.

Data on patient groups and treatment uptake levels were scarce. Such data were not available at the national or the hospital level. The required information was therefore collected directly from the hospital patients' records to be utilised in this study. Furthermore, the uptake levels were not consistent among different hospitals and sometimes between physicians. These two findings therefore highlight a lack of standardised healthcare provision and important gaps in the NCD health information system.

Modelling strengths and limitations {#s4a}
-----------------------------------

The modelling approach used in the study was comprehensive, it synthesised all the key risk factors and treatment options to help quantify changes in CHD mortality. Additionally, the model used rigorous sensitivity analyses to systematically examine the potential influence of uncertainties in the data (quality and sources) and model assumptions, and hence quantify the potential maximum and minimum effects of these contributory factors

This modelling approach also has obvious limitations. Notably, the extent and quantity of available data on CHD risk factor trends and treatment uptake. Furthermore, the model tended to overestimate the number of deaths averted in almost all age groups, especially among women. This may reflect less precision in female data. However, the data used in this model was generally of good quality. Mortality data were obtained from MOH death registry. Death registry data were evaluated in previous studies as medium quality based on the WHO criteria.[@R31] The demographic information was obtained from census data, and the risk factor trends were obtained from well-designed epidemiological studies and national PCBS, MOH and WHO surveys. Treatment uptake and patient group data were obtained from an extensive hospital-based survey conducted in 2009. Very scarce data available on treatment uptake were also obtained. However, researchers had to conduct additional surveys to get the timely, accurate data required by the model. Certain assumptions were needed to fill in the gaps for missing information. For instance, assumptions were made for the small group aged 65--74 years where risk factor information were not available. Assumption on treatment uptake at the starting point was also based on expert opinions working in the system for more than 10 years. Estimates of treatment uptake were collated from international and regional literature then validated with the expert opinions. The generalisation of efficiency estimates from meta-analysis of controlled clinical trials to effectiveness in clinical practice in the West Bank setting were clearly optimistic, and may have resulted in an overestimate of the true treatment benefits.

All these assumptions are transparent, being systematically detailed in the [appendix](http://.oxfordjournals.org/lookup/suppl/doi:10.1093//bmjopen-2012-001061/-/DC1), supported by local expert opinions and literature from the region and included in the sensitivity analyses. By good luck, the overall model fit approached 100%. However, it should be noted that fit within specific age groups was much less perfect.

Public health implications {#s4b}
--------------------------

CHD mortality fell by 20% between 1998 and 2009 in the West Bank, oPt. More than two-third of this fall was due to changes in major risk factors mainly total cholesterol, blood pressure and smoking.

Our results clearly indicate that risk factor improvements in the general population saved substantially more lives than specific treatments for individual patients. This emphasizes the importance of population-wide primary prevention strategies. Such strategies should also emphasize the risk factors which had a negative effect on the reduction of CHD in the model especially, diabetes, BMI and increased levels of physical inactivity. The Palestinian policy and strategic plan for NCD had focused on health diet and physical activity as its second and third policy objectives (MOH).[@R32]
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